Research and Development

As a global biopharmaceutical company with a focus on innovation and specialty care, we have the ambition to build a robust, valuable, and sustainable portfolio of medicines to meet patients and their healthcare teams’ needs.

Our R&D strategy

At Ipsen, our research decisions are guided by patient outcomes. Emphasizing a culture of open innovation, we focus our R&D efforts on accelerating prioritized internal projects while actively sourcing external assets. Our R&D strategy reinforces our focus on in our three main areas: oncology, rare disease and neuroscience. As we target differentiated medicines in these core areas, we will add ground-breaking new treatments to our portfolio. We will also maximize the value of our current pipeline assets.

As a global biopharmaceutical company with a focus on innovation and specialty care, we have the ambition to build a robust, valuable, and sustainable portfolio of medicines to meet patients and their healthcare teams’ needs. We have a focused approach and prioritize best-in-class collaborations for new, emerging products in oncology, rare disease, and neuroscience – areas where we have proven experience and global capabilities along with a strong network of partners.

Strengthening the pipeline

Pipeline as of 29 July 2021
Phase I
Phase II
Phase III
Registration
Cabometyx® + atezolizumab
Solid tumors
IPN59011
Longer-acting neurotoxin
Ax
IPN10200
Longer-acting neurotoxin
Ax / Tx
IPN601301
FOP
Cabometyx® + atezolizumab
1L HCC
Cabometyx®
2L RR DTC2
Cabometyx® + atezolizumab
2L NSCLC3
Cabometyx® + atezolizumab
2L mCRPC3
Onivyde®
2L SCLC4
Onivyde®
1L PDAC3
Dysport® solution
Glabellar lines
Dysport®
NDO2
palovarotene®
FOP
  • Oncology
  • Rare disease
  • Neuroscience
Data shown as at the end of Q2 2021
  • Phase II ready
  • Regulatory submission expected in 2021
  • Regulatory submission expected in 2023
  • Regulatory submission expected in 2022
  • Ax: aesthetics
  • Tx: therapeutics
  • FOP: fibrodysplasia ossificans progressiva
  • HCC: hepatocellular carcinoma
  • RR DTC: radio-refractory differentiated thyroid cancer
  • NSCLC: non-small cell lung cancer
  • mCRPC: metastatic castrate-resistant prostate cancer
  • SCLC: small cell lung cancer
  • PDAC: pancreatic ductal adenocarcinoma
  • NDO: neurogenic detrusor overactivity
  • 1L: first line
  • 2L: second line

Patients Are at the Forefront of Everything We Do

We deliver treatments that make a real, direct difference in patients’ daily lives and partner with the entire healthcare ecosystem to ensure they have access to them. By putting people living with the disease at the center of everything we do, we create support solutions that meet the real needs of patients and can help improve their lives.

Patient centricity means collaborating across the entire company, from R&D to post-marketing, to identify unmet needs and deliver outcomes that genuinely improve people’s lives as defined by patients themselves. This focus on people, on finding new ways to make a difference for them, is the foundation of everything we do.

The Importance of Partnership

We believe that great partnerships create great possibilities. We are on a mission to deliver at least one new molecular entity or meaningful indication each year and collaborations with other like-minded innovators are key for the next phase of our growth. Our partners possess a shared energy to create meaningful differences with a sense of urgency and passion to drive programs forward.

We form robust, integrated teams across the company to ensure we are harnessing the skills of both organizations to drive work forward as one team. We work with our partners to define a shared vision to unlock the full potential of their assets, achieving mutual success for our partners and Ipsen.

Our R&D and business development strategies allow us to take full advantage of the accelerated speed of scientific development to develop targeted treatments to deliver value to all the disease communities we serve.

The Future

We aspire to acquire new medicines that are aligned with our focus and that bring synergies to our existing capabilities. We intend to deliver high double-digit growth by implementing our R&D transformation with a focus on innovative and differentiated therapeutics, and bolstering our external sourcing model, at the same time as expanding our portfolio.

Where We Plan to Expand

Oncology

  • Investigational assets or a novel preclinical approach in both solid tumors and blood cancers, including niche tumors and broader populations with a biomarker segmentation
  • High unmet need oncology indications

Rare Disease

  • Disease areas with unmet need including bone and hormone disorders
  • Established and emerging modalities and gene-based therapies
  • All stages from late preclinical to marketed products

Neuroscience

  • Recombinant neurotoxins
  • Rare neurodegenerative and neuroinflammatory and movement disorders
  • Technologies to enhance Ipsen’s neurotoxin therapies and R&D capabilities

Our R&D Power Bases

Our main R&D centers are in world-class scientific hubs to take advantage of the networking opportunities and to progress our external innovation philosophy within established scientific ecosystems. Our three main sites are connected as an ‘innovation grid’, sharing real-time information, allowing us to adapt and focus capabilities to maximize our search and evaluation strategies on a global scale.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2021